PD-1/PD-L1 blockades in non-small-cell lung cancer therapy

OncoTargets and Therapy
Wang JingHui Zhu

Abstract

Lung cancer is the leading cause of cancer death in males and the second leading cause of death in females worldwide. Non-small-cell lung cancer (NSCLC) is the main pathological type of lung cancer, and most newly diagnosed NSCLC patients cannot undergo surgery because the disease is already locally advanced or metastatic. Despite chemoradiotherapy and targeted therapy improving clinical outcomes, overall survival remains poor. Immune checkpoint blockade, especially blockade of programmed death-1 (PD-1) receptor and its ligand PD-L1, achieved robust responses and improved survival for patients with locally advanced/metastatic NSCLC in preclinical and clinical studies. However, with regard to PD-1/PD-L1 checkpoint blockade as monotherapy or in combination with other antitumor therapies, such as chemotherapy, radiotherapy (including conventional irradiation and stereotactic body radiotherapy), and target therapy, there are still many unknowns in treating patients with NSCLC. Despite this limited understanding, checkpoint blockade as a novel therapeutic approach may change the treatment paradigm of NSCLC in the future. Here we review the main results from completed and ongoing studies to investigate the feasibility of PD-1/PD-L1 i...Continue Reading

Citations

Aug 27, 2016·Expert Opinion on Biological Therapy·Zvia AgurOfer Shlagman
Nov 15, 2016·Expert Review of Anticancer Therapy·Gautam Kishore ValechaJean Paul Atallah
Dec 21, 2016·Cancer Biotherapy & Radiopharmaceuticals·Zheng DongZhiguang Geng
Jan 26, 2017·Acta Pharmaceutica Sinica. B·Minting LinJianye Zhang
Jun 21, 2017·International Journal of Molecular Sciences·Ying-Ying LiNiramol Savaraj
Aug 25, 2017·Cell Death & Disease·Elisabetta CavalcantiMaria Lucia Caruso
Jul 31, 2019·Expert Opinion on Investigational Drugs·Alvaro H Ingles GarcesJames Larkin
Jul 26, 2019·The Clinical Respiratory Journal·Yuika SasataniHiroaki Satoh
Sep 7, 2017·Current Opinion in Oncology·Leora Boussi, Ruben Niesvizky
Apr 8, 2016·Current Opinion in Pediatrics·Lesley Doughty
Oct 6, 2018·Oncoimmunology·Sang-Soo KimEsther H Chang
Jun 27, 2019·International Journal of Cancer. Journal International Du Cancer·Sang-Soo KimEsther H Chang
Aug 4, 2016·Current Oncology Reports·Raffaele CalifanoAntonio Rossi
Aug 30, 2019·Experimental Hematology & Oncology·Zhenbin QiuWenzhao Zhong
Feb 1, 2022·Journal of Managed Care & Specialty Pharmacy·Sachin Kamal-BahlRichard Willke

❮ Previous
Next ❯

Software Mentioned

INSPIRE
RECIST
SQUIRE
ATLANTIC

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.